P&G Q4 update
This article was originally published in The Rose Sheet
Executive Summary
Sales projected to grow 6%-7% in the fourth quarter (ending June 30) with foreign exchange expected to contribute 3%-4% to the top line and acquisitions and divestitures to have a negative 1% impact, Procter & Gamble reports June 5. Sales expectations have been adjusted to reflect impact of a tornado that struck firm's Jackson, Tenn. Pringles manufacturing facility in May. Core earnings per share, excluding restructuring charges, are expected to grow 12%. Separately, P&G says it is launching additional tender offer period for Wella shareholders June 6 and will not change offer price for voting shares and preference shares during that period. P&G acquired approximately 5 mil. voting shares and 1.5 mil. preference shares, representing total of 9.69% of registered share capital during initial tender period...
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.